BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of…
Read More »BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of…
Read More »